Industry Sponsored Program
| THURSDAY, MARCH 21, 2024 | ||
| 13:00-14:00 | Horizon Industry Sponsored Symposium | PLENARY HALL Are imaging (MRI) and biomarkers useful tools for disease monitoring in NMOSD? Chair: Prof. Jaqueline Palace, John Radcliffe University Hospital, Oxford, UK Pro: Prof. Celia Oreja-Guevara, University Hospital San Carlos, Madrid, Spain Con: Prof. Friedemann Paul, Charite Universitätsmedizin, Berlin, Germany |  |
| 14:10-15:00 | Meet the Expert Session sponsored by Eisai | MTE 2 HALL The scientific case for biomarkers in Alzheimer’s disease Prof. Sir John Hardy, UCL Queen Square Institute of Neurology, London |  |
| FRIDAY, MARCH 22, 2024 | ||
| 13:40-14:30 | Meet the Expert Session sponsored by Merck | MTE 1 HALL Real world data with Cladribine from Jerusalem, more than 5 years of experience Dr. Petrou Panayiota, Israel |  |
| 13:30-14:00 | Meet the Expert Session sponsored by Amneal | MTE 2 HALL Emerging perspectives on COMT inhibition in treatment for Parkinson’s disease. Expert Panel Discussion: Moderator: Salima Brillman, USA Capsule: Levodopa pulsatility is associated with motor fluctuations. Should pharmacotherapy strategies utilizing COMT inhibition to lower levodopa fluctuation index be the goal for treating OFF? Who should be treated with the long acting COMT inhibitor opicapone? When and how should opicapone be added? Sagari Betté, USA; Fiona Gupta, USA; Ray Chaudhuri, UK; Lucia Batzu, UK |  |
| 14:00-14:30 | Meet the Expert Session sponsored by Cerevel | MTE 2 HALL Dopamine Receptors and Clinical Efficacy/Tolerability? Expert Panel Discussion: Moderator: Stuart Isaacson , USA Capsule: The use of dopamine agonists for the initial and adjunctive treatment of PD has become controversial, largely due to D2-family recptor related adverse effects, including impulse control disorders. However D1-specific dopamine agonis_The use of dopamine agonists for the initial and adjunctive treatment of PD has become controversial, largely due to D2-family recptor related adverse effects, incts such as tavapadon are in late-stage development and lack these D2-family associated side effects. Should dopamine agonists continue to play a role in PD? Daniel Weintraub, USA; Daniel Kremens, USA; Rajesh Pahwa, USA; Ray Chaudhuri, UK |  |
| SATURDAY, MARCH 23, 2024 | ||
| 12:30-13:30 | Sanofi Industry Sponsored Symposium | PLENARY HALL Using big data to drive advances and scientific discoveries in multiple sclerosis How can big data advance our understanding of MS? Prof. Tjalf Ziemssen, Germany Big data and scientific discoveries leading to new advances in MS research Prof. Sven Meuth, Germany |  |
| 13:40-14:30 | Meet the Expert Session sponsored by Novartis | MTE 1 HALL Identification of the optimal candidates for high efficacy B cell targeting therapies in MS - utilization of objective biomarkers Prof. Dimitrios Karussis, Israel |  |
